Fosun Pharma Listed in CCTV Financial 50 Index Sample Stock

HONG KONG, Aug. 13, 2013 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or the "Company"; stock code: 600196-SH, 02196-HK; and, together with its subsidiaries, the "Group"), a leading healthcare company in the PRC, announced company has been listed in "CCTV Financial 50 Index" Sample Stock.

As the market leader of the pharmaceutical industry in China, Fosun Pharma highly emphasizes the acceptance and implementation of social responsibilities. Recently, after the careful examination of CCTV Finance Index Expert Committee, Fosun Pharma was listed in the social responsibility dimension sample stock of "CCTV Financial 50 Index (399550)" and the "CCTV Financial 50 Responsibility Index (399555)". Announcement of index indicated that only three enterprises are listed in "CCTV 50 Index (399550)", with Fosun Pharma becoming the pioneer in the responsibility dimension.

"CCTV Financial 50 Index" is the index created by Shenzhen Securities Information Co., Ltd. and CCTV Finance Channel with the index code being "399550", or the index abbreviated as "CCTV 50". The index is the first A-stock index released by media with authority in China. To facilitate valued investment and enable sustainable development in listed companies, CCTV Finance Channel joined hands with five major tertiary institutions, namely Peking University, Fudan University, Renmin University of China, Nankai University and Central University of Finance and Economics to evaluate listed companies based on the five dimensions "growth, innovation, returns, corporate governance and social responsibility", with each dimension electing 10 A-stock listed companies and five dimensions giving 50 A-stock companies and forming sample stocks.

From 6 June 2013, to outline the market performance of outstanding enterprises under the five dimensions and to promote the further development of the relevant thematic investment and index investment, Shenzhen Securities Information Co., Ltd. joined hands with CCTV Finance Channel in releasing "CCTV Financial 50 Dimension Leading Index". "CCTV Financial 50 Dimension Leading Index" is an important composite of "CCTV Financial 50 Index" formed by the experts from China Association for Public Companies, the Chinese Institute of Certified Public Accountants, Dagong Global Credit Rating Co., Ltd. and five famous tertiary institutions conducting evaluations on listed companies based on the five dimensions of "growth, innovation, returns, corporate governance and social responsibility", with each dimension electing 50 A-stock companies and forming sample stocks. "CCTV Financial 50 Index" is composed of "Pure Price Index" and "Total Return Index" with the former releasing most up-to-date information about the stock market through the Shenzhen Stock Exchange Information System and the latter releasing information about the closing stock market through CNI Index.

Since 2008, Fosun Pharma has been publishing annual reports on social responsibility outlining its commitment to accept public supervision and continuously raise social responsibility awareness and its implementation standards. The company recorded spectacularly outstanding performance in such areas as the establishment of a prudent operation, the protection of the environment, the protection of staff rights, the emphasis on community well-being and the protection of consumer rights. With its commitment to "Innovation for Good Health", Fosun Pharma remains on its mission to promote health and well-being while bearing the principle of sustainability. The Company's strategic development approach of "Organic Growth, Coupled with Merge and Acquisition and Integration" allows it to continue to enhance creativity and service, drive integration and achieve capabilities of globalization. As a result, Fosun Pharma will emerge with an effective operation, world-class management, sound investments and as a leading provider of healthcare products and services.

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma)

Fosun Pharma is a leading healthcare company in the PRC. The Group was established in 1994 with headquarters located in Shanghai, and was listed on the Shanghai Stock Exchange in 1998. In October 2012, though the international financial environment was unfavorable, the Company successfully completed offering and listing H shares in Hong Kong. As a result, the Company has listings in both the A share market and the H share market. The Group has achieved significant results with strengthened corporate governance and investor relationship management. In addition to the SSE 180 Index, CSI 300 Index, SSE Dividend Index and SSE Corporate Governance Index, Fosun Pharma is also included in the SSE Private Enterprise 50 Index, SSE Social Responsibility Index and CCTV Financial 50 Index. According to IMS Health Incorporated ("IMS"), the Group was one of the top five domestic pharmaceutical companies in the PRC by revenue in the pharmaceutical manufacturing segment in 2011. The Group's business operations strategically cover multiple important segments in the healthcare industry value chain, with business segments including pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services and diagnostic products and medical devices.

Additional information about Fosun Pharma is available at http://www.fosunpharma.com.

For further information, please contact: